M&K Imports, LLC v. Rejuveneda Medical Group, Inc.

CourtDistrict Court, S.D. New York
DecidedJanuary 11, 2023
Docket7:22-cv-02606
StatusUnknown

This text of M&K Imports, LLC v. Rejuveneda Medical Group, Inc. (M&K Imports, LLC v. Rejuveneda Medical Group, Inc.) is published on Counsel Stack Legal Research, covering District Court, S.D. New York primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
M&K Imports, LLC v. Rejuveneda Medical Group, Inc., (S.D.N.Y. 2023).

Opinion

UNITED STATES DISTRICT COURT SOUTHERN DISTRICT OF NEW YORK ---------------------------------------------------------------x M&K IMPORTS, LLC, : Plaintiff, : : v. : OPINION AND ORDER :

REJUVENEDA MEDICAL GROUP, INC., : 22 CV 2606 (VB) d/b/a Regeneveda; THOM E. LOBE; PATRICK : D. CROCKER; and CROCKER LAW FIRM : PLLC a/k/a Crocker & Crocker, : Defendants. : ---------------------------------------------------------------x

Briccetti, J.: Plaintiff M&K Imports, LLC, brings this action against defendants Rejuveneda Medical Group, Inc., d/b/a/ Regeneveda (“Regeneveda”), Thom E. Lobe, Patrick D. Crocker, and Crocker Law Firm PLLC, asserting claims for breach of contract and aiding and abetting breach of fiduciary duty against Regeneveda and Lobe (the “Seller Defendants”); negligence, breach of fiduciary duty, and breach of escrow agreement against Crocker and Crocker Law Firm (together, the “Crocker Defendants”); and conversion against all defendants. Now pending is the Seller Defendants’ partial motion to dismiss the amended complaint (“Amended Complaint” or Am. Compl.”) under Rule 12(b)(6). (Doc. #44 (“Def. Mot.”)). For the reasons set forth below, the motion is GRANTED IN PART and DENIED IN PART. The Court has subject-matter jurisdiction pursuant to 28 U.S.C. § 1332(a). BACKGROUND For the purpose of ruling on the motion to dismiss, the Court accepts as true all well- pleaded allegations in the Amended Complaint and draws all reasonable inferences in plaintiff’s favor, as summarized below. Plaintiff alleges Regeneveda is a corporation wholly owned, operated, and directed by Lobe, a doctor. Lobe allegedly operates Regeneveda as his alter ego by conducting his medical practice and personal business through Regeneveda, but fails to capitalize Regeneveda sufficiently to meet its debts and obligations.

Plaintiff alleges it and Regeneveda, represented by Lobe, entered into a Supply Purchase Agreement (Doc. #39-1 (the “Original SPA”)) on January 13, 2022. Pursuant to the Original SPA, Regeneveda agreed to supply plaintiff with four million Flowflex COVID-19 at-home antigen tests (the “Tests”) in exchange for $23.6 million. Plaintiff further alleges it separately agreed to resell the Tests, once procured, to the City of New York (the “City”). The Original SPA established the following commitments: (i) Regeneveda would deliver two million tests by January 21, 2022, and the remaining two million tests by January 24, 2022; (ii) plaintiff would pay a deposit of $7.08 million (thirty percent of the contract price) by January 14, 2022 (the “Deposit”); (iii) the Deposit would be paid to escrow agent Crocker, who would deposit it into his IOLTA account (the “Escrow Account”); and (iv) plaintiff would pay the

remaining seventy percent of the contract price “upon receipt of a valid and acceptable SGS inspection report covering the Tests, or ‘upon satisfactory inspection and transfer of the goods.’” (Am. Compl. ¶ 34). The Original SPA also provided: [I]f [Regeneveda ]has not produced any documentation of an airway bill or confirmation of shipment no later than January 20, 2022 . . . [t]he 30% deposit will be returned into [plaintiff’s] account no later than January 21, 202[2]. If the 30% deposit has not been returned before January 21, 2022 the amount will accrued at a 1.5% interest per day until funds are fully returned back into [plaintiff’s] account.

(Id. Ex. A, ¶ 8.2). Plaintiff contends it wired the Deposit to the Escrow Account on January 14, 2022. Thereafter, plaintiff allegedly never received “an airway bill, confirmation of shipment, or SGS inspection report as required under the Original SPA. As such, the Deposit should have been returned” to plaintiff “and no funds should have been released from the Escrow Account except back to” plaintiff. (Am. Compl. ¶ 36). Nevertheless, plaintiff alleges that, unbeknownst to it, on January 18, 2022, Crocker disbursed $6.2 million of the Deposit from the Escrow Account to

Regeneveda’s Chinese supplier, even though plaintiff did not give Crocker or Lobe authority to release the funds. According to plaintiff, Crocker stated he released the funds based on instructions from Lobe and Regeneveda, among others. On January 20, 2022, Lobe allegedly sent plaintiff a letter of assurance stating the Tests would be delivered between January 25 and 26, 2022. According to the Amended Complaint, two days later, plaintiff and Regeneveda entered into an Amended Supply Purchase Agreement (the “Amended SPA”), which: (i) required delivery of the Tests between January 25 and 26, 2022; (ii) acknowledged Crocker’s receipt of the earlier $7.08 million Deposit; (iii) “did not disclose that Defendants had improperly released $6.2 million of those funds from the Escrow Account” (id. ¶ 42); and (iv) required plaintiff to pay an additional $11.8 million to the Escrow

Account on January 24, 2022. On January 24, 2022, plaintiff made the $11.8 million additional payment, but never received the requisite documentation. Finally, on January 31, 2022, Lobe wrote Crocker requesting that he return the $11.8 million additional payment to plaintiff, and Crocker complied. On February 3, 2022, given the delays, the City cancelled its order of the Tests from plaintiff. The next day, plaintiff advised Regeneveda of the City’s cancellation and demanded an immediate return of the Deposit. Thereafter, Lobe directed Crocker to return $750,000 to plaintiff. However, plaintiff alleges on March 8, 2022, it learned for the first time, through an email from Crocker, that Crocker had disbursed $6.2 million from the Escrow Account to Regeneveda’s supplier on January 18, 2022. On March 10, 2022, the Crocker Defendants wired plaintiff the Escrow Account balance of $130,000. According to plaintiff, $6.2 million of the Deposit has not been returned. DISCUSSION

I. Rule 12(b)(6) Standard of Review In deciding a Rule 12(b)(6) motion, the Court evaluates the sufficiency of the complaint under the “two-pronged approach” articulated by the Supreme Court in Ashcroft v. Iqbal, 556 U.S. 662, 679 (2009).1 First, a plaintiff’s legal conclusions and “[t]hreadbare recitals of the elements of a cause of action, supported by mere conclusory statements,” are not entitled to the assumption of truth and thus are not sufficient to withstand a motion to dismiss. Id. at 678; Hayden v. Paterson, 594 F.3d 150, 161 (2d Cir. 2010). Second, “[w]hen there are well-pleaded factual allegations, a court should assume their veracity and then determine whether they plausibly give rise to an entitlement to relief.” Ashcroft v. Iqbal, 556 U.S. at 679. To survive a Rule 12(b)(6) motion, the complaint’s allegations must meet a standard of

“plausibility.” Ashcroft v. Iqbal, 556 U.S. at 678; Bell Atl. Corp. v. Twombly, 550 U.S. 544, 564 (2007). A claim is facially plausible “when the plaintiff pleads factual content that allows the court to draw the reasonable inference that the defendant is liable for the misconduct alleged.” Ashcroft v. Iqbal, 556 U.S. at 678. “The plausibility standard is not akin to a ‘probability requirement,’ but it asks for more than a sheer possibility that a defendant has acted unlawfully.” Id. (quoting Bell Atl. Corp. v. Twombly, 550 U.S. at 556). “In considering a motion to dismiss for failure to state a claim pursuant to Rule 12(b)(6),

1 Unless otherwise indicated, case quotations omit all internal citations, quotation marks, footnotes, and alterations.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Bell Atlantic Corp. v. Twombly
550 U.S. 544 (Supreme Court, 2007)
Ashcroft v. Iqbal
556 U.S. 662 (Supreme Court, 2009)
DiFolco v. MSNBC Cable L.L.C.
622 F.3d 104 (Second Circuit, 2010)
Hayden v. Paterson
594 F.3d 150 (Second Circuit, 2010)
Automotriz Del Golfo De California v. Resnick
306 P.2d 1 (California Supreme Court, 1957)
Kirschner v. Bennett
648 F. Supp. 2d 525 (S.D. New York, 2009)
Sonnenblick-Goldman Co. v. ITT Corp.
912 F. Supp. 85 (S.D. New York, 1996)
Colavito v. New York Organ Donor Network, Inc.
860 N.E.2d 713 (New York Court of Appeals, 2006)
EBC I, Inc. v. Goldman, Sachs & Co.
832 N.E.2d 26 (New York Court of Appeals, 2005)
Zoran Corp. v. Chen
185 Cal. App. 4th 799 (California Court of Appeal, 2010)
Neilson v. Union Bank of California, N.A.
290 F. Supp. 2d 1101 (C.D. California, 2003)
Sheehy v. New Century Mortgage Corp.
690 F. Supp. 2d 51 (E.D. New York, 2010)
North Shore Architectural Stone, Inc. v. American Artisan Construction, Inc.
2017 NY Slip Op 6655 (Appellate Division of the Supreme Court of New York, 2017)
Sporn v. MCA Records, Inc.
448 N.E.2d 1324 (New York Court of Appeals, 1983)
Leek v. Cooper
194 Cal. App. 4th 399 (California Court of Appeal, 2011)
Talansky v. Schulman
2 A.D.3d 355 (Appellate Division of the Supreme Court of New York, 2003)
Kaufman v. Cohen
307 A.D.2d 113 (Appellate Division of the Supreme Court of New York, 2003)
Grocery Delivery E-Servs. USA, Inc. v. Flynn
201 A.D.3d 585 (Appellate Division of the Supreme Court of New York, 2022)
Sandoval v. Ali
34 F. Supp. 3d 1031 (N.D. California, 2014)

Cite This Page — Counsel Stack

Bluebook (online)
M&K Imports, LLC v. Rejuveneda Medical Group, Inc., Counsel Stack Legal Research, https://law.counselstack.com/opinion/mk-imports-llc-v-rejuveneda-medical-group-inc-nysd-2023.